2020 was a year for reinvigorating Avecho Biotechnology Limited (ASX:AVE) – cementing Company’s the rebrand, a change in CEO and a consolidated portfolio of products. Here to speak in this Q&A with StockPal is the Chief Executive Officer, Dr. Paul Gavin.
0:10 – Could you summarise for me what you set out to achieve in 2020?
1:15 – Could you tell me quickly what TPM is and its unique point of difference?
1:58 – Why is TPM a potential game changer for this CBD industry?
3:12 – Tell me about your interest in injectable products too?
4:21 – What activities and priorities are ahead to clinically test and commercialise these offerings in 2021?
5:29 – How did Avecho cope during the COVID-19 pandemic?
6:30 – How are you currently engaging with your investors/shareholders?
Visit Avecho’s website to learn more about their story: http://avecho.com.au/
Email if you are or represent a listed-company and is keen to be in our interviews.
Want to be on the list next time this company raises capital? Open an account with Fresh Equities and start exploring capital raises – freshequities.com
